Ra Capital Management, L.P. Buys 39,869 Shares of Hemab Therapeutics (NASDAQ:COAG) Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $24.81 per share, for a total transaction of $989,149.89. Following the completion of the acquisition, the insider owned 6,365,783 shares of the company’s stock, valued at approximately $157,935,076.23. The trade was a 0.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.98 per share, with a total value of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.60 per share, with a total value of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were acquired at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $25.90 on Wednesday. Hemab Therapeutics Holdings, Inc. has a twelve month low of $23.00 and a twelve month high of $36.61.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday.